| |
The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir/Sofosbuvir ± RBV in the Phase 3 ION Studies
|
| |
| |
......"lower SVR rates were not observed in treatment-naive subjects or with longer 24 week LDV/SOF treatment"
http://www.natap.org/2014/ResisWksp/ResisWksp_07.htm
---------------------------------
All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study.....http://www.natap.org/2014/EASL/EASL_32.htm
All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study......http://www.natap.org/2014/EASL/EASL_28.htm
|
|
| |
| |
|
|
|
